Vapotherm Inc
F:VA21
Vapotherm Inc
Total Receivables
Vapotherm Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
Vapotherm Inc
F:VA21
|
Total Receivables
$10.7m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Total Receivables
$2.8B
|
CAGR 3-Years
13%
|
CAGR 5-Years
13%
|
CAGR 10-Years
8%
|
|
|
Stryker Corp
NYSE:SYK
|
Total Receivables
$4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
8%
|
CAGR 10-Years
9%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Total Receivables
$8.1B
|
CAGR 3-Years
9%
|
CAGR 5-Years
5%
|
CAGR 10-Years
9%
|
|
|
IDEXX Laboratories Inc
NASDAQ:IDXX
|
Total Receivables
$715m
|
CAGR 3-Years
13%
|
CAGR 5-Years
14%
|
CAGR 10-Years
14%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Total Receivables
$1.5B
|
CAGR 3-Years
17%
|
CAGR 5-Years
19%
|
CAGR 10-Years
15%
|
|
Vapotherm Inc
Glance View
Vapotherm, Inc. is a medical technology company, which engages in the development and commercialization of medical devices for patients suffering from respiratory distress. The company is headquartered in Exeter, New Hampshire and currently employs 510 full-time employees. The company went IPO on 2018-11-14. The firm is focused on the care of patients of all ages suffering from the respiratory distress often associated with complex lung diseases, such as chronic obstructive pulmonary disease (COPD), congestive heart failure (CHF), pneumonia, asthma and COVID-19. Its device solutions are focused on high velocity nasal insufflation (HVNI), which delivers non-invasive ventilatory support to patients suffering from respiratory distress. Its HVNI technology delivers heated, humidified and oxygenated air at a high velocity through a small-bore nasal interface. The company offers four versions of its Precision Flow systems, which includes Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic and Precision Flow Heliox. Its Precision Flow systems include a capital unit, a single-use disposable and a nasal interface. Its digital solutions are focused on at home patient monitoring. The firm also provides various clinical solutions.
See Also
What is Vapotherm Inc's Total Receivables?
Total Receivables
10.7m
USD
Based on the financial report for Dec 31, 2023, Vapotherm Inc's Total Receivables amounts to 10.7m USD.
What is Vapotherm Inc's Total Receivables growth rate?
Total Receivables CAGR 5Y
8%
Over the last year, the Total Receivables growth was 17%. The average annual Total Receivables growth rates for Vapotherm Inc have been -23% over the past three years , 8% over the past five years .
